Jean Holloway Sells 3,079 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 3,079 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $115,739.61. Following the completion of the sale, the senior vice president directly owned 153,871 shares in the company, valued at $5,784,010.89. This represents a 1.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Stock Up 0.9%

NYSE:AORT traded up $0.31 during trading hours on Wednesday, hitting $35.66. The company’s stock had a trading volume of 300,261 shares, compared to its average volume of 399,410. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $1.71 billion, a P/E ratio of 178.32 and a beta of 1.59. The stock has a fifty day moving average of $42.51 and a 200-day moving average of $43.14.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC lifted its position in Artivion by 20.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after acquiring an additional 63,205 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Artivion in the second quarter valued at approximately $664,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Artivion during the second quarter worth approximately $669,000. Sio Capital Management LLC raised its stake in shares of Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after purchasing an additional 37,558 shares during the last quarter. Finally, Atria Investments Inc acquired a new stake in shares of Artivion during the second quarter worth $244,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AORT. Citizens Jmp boosted their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Canaccord Genuity Group decreased their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Oppenheimer reissued an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.